FrancophonIA/ELRC3.0 huggingface dataset:
English: Multiple gestation, especially high order, carries an increased risk of adverse maternal (pregnancy and delivery complications) and perinatal (low birth weight) outcomes.For anovulatory women undergoing ovulation induction, monitoring follicular development with transvaginal ultrasonography may aid in determining whether or not to continue the cycle in order to reduce the risk of multiple pregnancies.
Estonian: Anovulatsiooniga naistel, kellel indutseeritakse ovulatsiooni, võib follikulaarse arengu jälgimine transvaginaalse ultrasonograafiaga aidata määrata, kas jätkata tsüklit või mitte, selleks et vähendada mitmikraseduse riski.
English: Breast complaints Metrorrhagia Ovarian cyst Ovarian enlargement Ovarian torsion Uterine enlargement Vaginal haemorrhage
Estonian: Munasarja tsüst Munasarjade suurenemine Munasarjade torsioon Emaka suurenemine Vaginaalne hemorraagia
English: Multiple pregnancies and births have been reported for all gonadotropin treatments, including Puregon.
Estonian: Kõikide gonadotropiini ravimitega, sh Puregon'iga, on teatatud mitmikrasedustest ja mitmike sündidest.
English: Puregon may affect milk production.
Estonian: Puregon võib avaldada mõju rinnapiima tootlusele.
English: VIAL TEXT Puregon 225 IU/0.5 mL
Estonian: VIAALI TEKST Puregon 225 RÜ/0,5 ml
English: Puregon solution for injection is designed for use in conjunction with the Puregon Pen.
Estonian: Puregon süstelahus on mõeldud kasutamiseks Puregon Pen pensüsteliga.
English: Puregon 150 IU/0.18 mL solution for injection Puregon 300 IU/0.36 mL solution for injection Puregon 600 IU/0.72 mL solution for injection Puregon 900 IU/1.08 mL solution for injection
Estonian: Puregon 150 RÜ/0,18 ml süstelahus Puregon 300 RÜ/0,36 ml süstelahus Puregon 600 RÜ/0,72 ml süstelahus Puregon 900 RÜ/1,08 ml süstelahus
English: N.V. Organon
Estonian: N.V.
English: The administration of Puregon is then discontinued and ovulation can be induced by administering human chorionic gonadotrophin (hCG).
Estonian: Seejärel lõpetatakse Puregon'i manustamine ning ovulatsiooni indutseerimiseks manustatakse inimese kooriongonadotropiini (hCG).
English: Puregon 50 IU/0.5 mL solution for injection Puregon 75 IU/0.5 mL solution for injection Puregon 100 IU/0.5 mL solution for injection Puregon 150 IU/0.5 mL solution for injection Puregon 200 IU/0.5 mL solution for injection Puregon 225 IU/0.5 mL solution for injection
Estonian: Puregon 50 RÜ/0,5 ml süstelahus Puregon 75 RÜ/0,5 ml süstelahus Puregon 100 RÜ/0,5 ml süstelahus Puregon 150 RÜ/0,5 ml süstelahus Puregon 200 RÜ/0,5 ml süstelahus Puregon 225 RÜ/0,5 ml süstelahus
English: VIAL TEXT Puregon 75 IU/0.5 mL
Estonian: VIAALI TEKST Puregon 75 RÜ/0,5 ml
English: Puregon 50 IU/0.5 mL solution for injection Puregon 75 IU/0.5 mL solution for injection Puregon 100 IU/0.5 mL solution for injection Puregon 150 IU/0.5 mL solution for injection Puregon 200 IU/0.5 mL solution for injection Puregon 225 IU/0.5 mL solution for injection follitropin beta
Estonian: Puregon 50 RÜ/0,5 ml süstelahus Puregon 75 RÜ/0,5 ml süstelahus Puregon 100 RÜ/0,5 ml süstelahus Puregon 150 RÜ/0,5 ml süstelahus Puregon 200 RÜ/0,5 ml süstelahus Puregon 225 RÜ/0,5 ml süstelahus follitropiin beeta
English: Puregon 150 IU/0.18 mL solution for injection Puregon 300 IU/0.36 mL solution for injection Puregon 600 IU/0.72 mL solution for injection Puregon 900 IU/1.08 mL solution for injection follitropin beta
Estonian: Puregon 150 RÜ/0,18 ml süstelahus Puregon 300 RÜ/0,36 ml süstelahus Puregon 600 RÜ/0,72 ml süstelahus Puregon 900 RÜ/1,08 ml süstelahus follitropiin beeta
English: Ovarian and Other Reproductive System Tumours There have been reports of ovarian and other reproductive system tumors in women who have had infertility treatment.
Estonian: Munasarjade ja muud reproduktiivsüsteemi kasvajad Viljatusravi saavatel naistel on teatatud munasarjade ja teistest reproduktiivsüsteemi kasvajatest.
English: OUTER CARTON TEXT Puregon 900 IU/1.08 mL 1 cartridge
Estonian: TEKST VÄLISPAKENDIL Puregon 900 RÜ/1,08 ml 1 kolbampull
English: Solution for injection 1 vial containing 0.5 mL 5 vials each containing 0.5 mL 10 vials each containing 0.5 mL
Estonian: Süstelahus 1 x 0,5 ml viaal 5 x 0,5 ml viaali 10 x 0,5 ml viaali
English: CARTRIDGE TEXT Puregon 900 IU/1.08 mL
Estonian: TEKST KOLBAMPULLIL Puregon 900 RÜ/1,08 ml
English: CARTRIDGE TEXT Puregon 300 IU/0.36 mL
Estonian: TEKST KOLBAMPULLIL Puregon 300 RÜ/0,36 ml
English: 2 packs with 3 pen needles
Estonian: 2 pakendit, igaühes 3 süstlanõela
English: This leaflet was last revised in Month YYYY
Estonian: Infoleht on viimati uuendatud KK/AAAA.
English: Puregon 900 IU/1.08 mL injection follitropin beta
Estonian: Puregon 900 RÜ/1,08 ml süstelahus follitropiin beeta
English: CARTRIDGE TEXT Puregon 600 IU/0.72 mL
Estonian: TEKST KOLBAMPULLIL Puregon 600 RÜ/0,72 ml
English: 3 packs with 3 pen needles
Estonian: 3 pakendit, igaühes 3 süstlanõela
English: OUTER CARTON TEXT Puregon 300 IU/0.36 mL 1 cartridge
Estonian: TEKST VÄLISPAKENDIL Puregon 300 RÜ/0,36 ml 1 kolbampull
English: This corresponds to a strength of 450 IU/mL.
Estonian: See vastab tugevusele 450 RÜ/ml.
English: OUTER CARTON TEXT Puregon 150 IU/0.18 mL 1 cartridge
Estonian: TEKST VÄLISPAKENDIL Puregon 150 RÜ/0,18 ml 1 kolbampull
English: Puregon 300 IU/0.36 mL solution for injection EU/1/96/008/038
Estonian: Puregon 300 RÜ/0,36 ml süstelahus EU/1/96/008/038
English: Clinical use of Puregon by the intramuscular or subcutaneous routes may lead to local reactions at the site of injection (3% of all patients treated).
Estonian: Sageli (3% ravi saanud patsientidest) on täheldatud, et Puregon'i kliiniline intramuskulaarne või subkutaanne manustamine võib põhjustada manustamiskoha reaktsioone.
English: Too high a dose of Puregon may cause hyperstimulation of the ovaries (OHSS).
Estonian: Liiga suur Puregon'i annus võib tekitada OHSS-i. Seda võib tunda kõhuvaluna.
English: CARTRIDGE TEXT Puregon 150 IU/0.18 mL
Estonian: TEKST KOLBAMPULLIL Puregon 150 RÜ/0,18 ml
English: 1 pack with 3 pen needles
Estonian: 1 kolbampull pakendis 3 süstlanõela
English: Puregon 600 IU/0.72 mL injection follitropin beta
Estonian: Puregon 600 RÜ/0,72 ml süstelahus follitropiin beeta
English: VIAL TEXT Puregon 200 IU/0.5 mL
Estonian: VIAALI TEKST Puregon 200 RÜ/0,5 ml
English: Puregon 225 IU/0.5 mL injection follitropin beta
Estonian: Puregon 225 RÜ/0,5 ml süstelahus follitropiin beeta
English: Puregon 600 IU/0.72 mL solution for injection EU/1/96/008/039
Estonian: Puregon 600 RÜ/0,72 ml süstelahus EU/1/96/008/039
English: Puregon solution for injection (injection) is a clear, colourless liquid.
Estonian: Puregoni süstelahus (süstevedelik) on selge, värvusetu vedelik ja on saadaval klaasist kolbampullis.
English: OUTER CARTON TEXT Puregon 600 IU/0.72 mL 1 cartridge
Estonian: TEKST VÄLISPAKENDIL Puregon 600 RÜ/0,72 ml 1 kolbampull
English: Puregon 300 IU/0.36 mL injection follitropin beta
Estonian: Puregon 300 RÜ/0,36 ml süstelahus follitropiin beeta
English: 1 vial contains 0.5 mL follitropin beta corresponding to: 225 IU (450 IU/mL) recombinant follicle-stimulating hormone (FSH) activity.
Estonian: 1 viaal sisaldab 0,5 ml follitropiin beetat, mis vastab 225 RÜ (450 RÜ/ml) rekombinantse folliikuleid stimuleeriva hormooni (FSH) aktiivsusele.
English: Puregon 150 IU/0.18 mL solution for injection EU/1/96/008/040
Estonian: Puregon 150 RÜ/0,18 ml süstelahus EU/1/96/008/040
English: OUTER CARTON TEXT Puregon 75 IU/0.5 mL 1, 5 or 10 vials
Estonian: VÄLISPAKENDI TEKST Puregon 75 RÜ/0,5 ml 1, 5 või 10 viaali
English: Puregon 75 IU/0.5 mL injection follitropin beta
Estonian: Puregon 75 RÜ/0,5 ml süstelahus follitropiin beeta
English: Puregon 75 IU/0.5 mL solution for injection: Each vial contains the active substance follitropin beta, a hormone known as follicle-stimulating hormone (FSH), in a strength of 75 IU in 0.5 mL aqueous solution per vial.
Estonian: Puregon 75 RÜ/0,5 ml süstelahus: Üks viaal sisaldab toimeainet follitropiin beeta, mis on tuntud kui folliikuleid stimuleeriv hormoon (FSH), 75 RÜ/0,5 ml vesilahus viaalis.
English: VIAL TEXT Puregon 50 IU/0.5 mL
Estonian: VIAALI TEKST Puregon 50 RÜ/0,5 ml
English: OUTER CARTON TEXT Puregon 225 IU/0.5 mL 1, 5 or 10 vials
Estonian: VÄLISPAKENDI TEKST Puregon 225 RÜ/0,5 ml 1, 5 või 10 viaali
English: Puregon 225 IU/0.5 mL solution for injection EU/1/96/008/032
Estonian: Puregon 225 RÜ/0,5 ml süstelahus EU/1/96/008/032
English: Puregon 225 IU/0.5 mL solution for injection: Each vial contains the active substance follitropin beta, a hormone known as follicle-stimulating hormone (FSH), in a strength of 225 IU in 0.5 mL aqueous solution per vial.
Estonian: Puregon 225 RÜ/0,5 ml süstelahus: Üks viaal sisaldab toimeainet follitropiin beeta, mis on tuntud kui folliikuleid stimuleeriv hormoon (FSH), 225 RÜ/0,5 ml vesilahus viaalis.
English: Puregon 900 IU/1.08 mL solution for injection EU/1/96/008/041
Estonian: Puregon 900 RÜ/1,08 ml süstelahus EU/1/96/008/041
English: Ovarian torsion has occurred after treatment with gonadotropins including Puregon.
Estonian: Pärast ravi gonadotropiinidega (sh Puregon'iga) on esinenud munasarjade torsiooni.
English: Puregon 75 IU/0.5 mL solution for injection EU/1/96/008/020
Estonian: Puregon 75 RÜ/0,5 ml süstelahus EU/1/96/008/020
English: Puregon 225 IU/0.5 mL solution for injection
Estonian: Puregon 225 RÜ/0,5 ml süstelahus
English: One vial contains 225 IU recombinant follicle-stimulating hormone (FSH) in 0.5 mL aqueous solution.
Estonian: Üks viaal sisaldab 225 RÜ rekombinantset folliikuleid stimuleerivat hormooni (FSH) 0,5 ml vesilahuses.
English: VIAL TEXT Puregon 100 IU/0.5 mL
Estonian: VIAALI TEKST Puregon 100 RÜ/0,5 ml
English: Puregon 300 IU/0.36 mL solution for injection
Estonian: Puregon 300 RÜ/0,36 ml süstelahus
English: One vial contains 22.5 microgram of protein (specific in vivo bioactivity equal to approximately 10,000 IU FSH / mg protein).
Estonian: Üks viaal sisaldab 22,5 mikrogrammi proteiini (spetsiifiline biosaadavus in vivo on võrdne umbes vahekorras 10 000 RÜ FSH / mg proteiini).
English: Ovarian torsion has been reported after treatment with gonadotropins, including Puregon.
Estonian: Pärast ravi gonadotropiinide, sh Puregon'iga, on täheldatud munasarja torsiooni.
English: Puregon 600 IU/0.72 mL solution for injection
Estonian: Puregon 600 RÜ/0,72 ml süstelahus
English: Puregon 150 IU/0.5 mL solution for injection EU/1/96/008/026
Estonian: Puregon 150 RÜ/0,5 ml süstelahus EU/1/96/008/026
English: Puregon 200 IU/0.5 mL solution for injection EU/1/96/008/029
Estonian: Puregon 200 RÜ/0,5 ml süstelahus EU/1/96/008/029
English: Puregon 100 IU/0.5 mL solution for injection EU/1/96/008/023
Estonian: Puregon 100 RÜ/0,5 ml süstelahus EU/1/96/008/023
English: Puregon 900 IU/1.08 mL solution for injection
Estonian: Puregon 900 RÜ/1,08 ml süstelahus
English: Puregon 150 IU/0.18 mL injection follitropin beta
Estonian: Puregon 150 RÜ/0,18 ml süstelahus follitropiin beeta
English: Puregon 150 IU/0.5 mL solution for injection: Each vial contains the active substance follitropin beta, a hormone known as follicle-stimulating hormone (FSH), in a strength of 150 IU in 0.5 mL aqueous solution per vial.
Estonian: Puregon 150 RÜ/0,5 ml süstelahus: Üks viaal sisaldab toimeainet follitropiin beeta, mis on tuntud kui folliikuleid stimuleeriv hormoon (FSH), 150 RÜ/0,5 ml vesilahus viaalis.
English: Puregon 50 IU/0.5 mL solution for injection EU/1/96/008/017
Estonian: Puregon 50 RÜ/0,5 ml süstelahus EU/1/96/008/017
English: One vial contains 7.5 microgram of protein (specific in vivo bioactivity equal to approximately 10,000 IU FSH / mg protein).
Estonian: Üks viaal sisaldab 7,5 mikrogrammi proteiini (spetsiifiline biosaadavus in vivo on võrdne umbes vahekorras 10 000 RÜ FSH / mg proteiini).
English: Puregon 200 IU/0.5 mL injection follitropin beta
Estonian: Puregon 200 RÜ/0,5 ml süstelahus follitropiin beeta
English: In rare instances, thromboembolism has been associated with follitropin beta /hCG therapy as with other gonadotrophins.
Estonian: Harvadel juhtudel on gonadotropiinidega ravimisel esinenud trombembooliat.
English: Puregon 200 IU/0.5 mL solution for injection: Each vial contains the active substance follitropin beta, a hormone known as follicle-stimulating hormone (FSH), in a strength of 200 IU in 0.5 mL aqueous solution per vial.
Estonian: Puregon 200 RÜ/0,5 ml süstelahus: Üks viaal sisaldab toimeainet follitropiin beeta, mis on tuntud kui folliikuleid stimuleeriv hormoon (FSH), 200 RÜ/0,5 ml vesilahus viaalis.
English: OUTER CARTON TEXT Puregon 150 IU/0.5 mL 1, 5 or 10 vials
Estonian: VÄLISPAKENDI TEKST Puregon 150 RÜ/0,5 ml 1, 5 või 10 viaali
English: OUTER CARTON TEXT Puregon 200 IU/0.5 mL 1, 5 or 10 vials
Estonian: VÄLISPAKENDI TEKST Puregon 200 RÜ/0,5 ml 1, 5 või 10 viaali
English: Puregon 150 IU/0.18 mL solution for injection
Estonian: Puregon 150 RÜ/0,18 ml süstelahus
English: Puregon 150 IU/0.5 mL injection follitropin beta
Estonian: Puregon 150 RÜ/0,5 ml süstelahus follitropiin beeta
English: VIAL TEXT Puregon 150 IU/0.5 mL
Estonian: VIAALI TEKST Puregon 150 RÜ/0,5 ml
English: You should use sterile disposable syringes and needles for the administration of Puregon.
Estonian: Puregon'i manustamisel peate kasutama steriilseid, ühekordse kasutusega süstlaid ja nõelu.
English: Puregon 75 IU/0.5 mL solution for injection
Estonian: Puregon 75 RÜ/0,5 ml süstelahus
English: Puregon 50 IU/0.5 mL injection follitropin beta
Estonian: Puregon 50 RÜ/0,5 ml süstelahus follitropiin beeta
English: OUTER CARTON TEXT Puregon 50 IU/0.5 mL 1, 5 or 10 vials
Estonian: VÄLISPAKENDI TEKST Puregon 50 RÜ/0,5 ml 1, 5 või 10 viaali
English: Local reactions at the site of injection include: bruising, pain, redness, swelling and itching 3.
Estonian: Süstekoha lokaalsete reaktsioonide hulka kuuluvad: verevalum, valulikkus, punetus, turse ja sügelemine Generaliseerunud ülitundlikkusreaktsiooni hulka kuuluvad erüteem, urtikaaria, lööve ja kihelus
English: OUTER CARTON TEXT Puregon 100 IU/0.5 mL 1, 5 or 10 vials
Estonian: VÄLISPAKENDI TEKST Puregon 100 RÜ/0,5 ml 1, 5 või 10 viaali
English: Puregon 100 IU/0.5 mL solution for injection: Each vial contains the active substance follitropin beta, a hormone known as follicle-stimulating hormone (FSH), in a strength of 100 IU in 0.5 mL aqueous solution per vial.
Estonian: Puregon 100 RÜ/0,5 ml süstelahus: Üks viaal sisaldab toimeainet follitropiin beeta, mis on tuntud kui folliikuleid stimuleeriv hormoon (FSH), 100 RÜ/0,5 ml vesilahus viaalis.
English: 1.08 mL of solution in 1.5 mL cartridge (type I glass) with a grey rubber piston and an aluminium crimp-cap with a rubber inlay.
Estonian: Puregon'i süstelahuse 900 RÜ/1,08 ml karp sisaldab 1 kolbampulli (1,5 ml) follitropiin beetat ja 9 süstenõela kasutamiseks koos Puregon Pen pensüsteliga.
English: One vial contains 5 microgram of protein (specific in vivo bioactivity equal to approximately 10,000 IU FSH / mg protein).
Estonian: Üks viaal sisaldab 5 mikrogrammi proteiini (spetsiifiline biosaadavus in vivo on võrdne umbes vahekorras 10 000 RÜ FSH / mg proteiini).
English: Puregon 50 IU/0.5 mL solution for injection: Each vial contains the active substance follitropin beta, a hormone known as follicle-stimulating hormone (FSH), in a strength of 50 IU in 0.5 mL aqueous solution per vial.
Estonian: Puregon 50 RÜ/0,5 ml süstelahus: Üks viaal sisaldab toimeainet follitropiin beeta, mis on tuntud kui folliikuleid stimuleeriv hormoon (FSH), 50 RÜ/0,5 ml vesilahus viaalis.
English: Puregon 100 IU/0.5 mL injection follitropin beta
Estonian: Puregon 100 RÜ/0,5 ml süstelahus follitropiin beeta
English: One vial contains 20 microgram of protein (specific in vivo bioactivity equal to approximately 10,000 IU FSH / mg protein).
Estonian: Üks viaal sisaldab 20 mikrogrammi proteiini (spetsiifiline biosaadavus in vivo on võrdne umbes vahekorras 10 000 RÜ FSH / mg proteiini).
English: One vial contains 15 microgram of protein (specific in vivo bioactivity equal to approximately 10,000 IU FSH / mg protein).
Estonian: Üks viaal sisaldab 15 mikrogrammi proteiini (spetsiifiline biosaadavus in vivo on võrdne umbes vahekorras 10 000 RÜ FSH / mg proteiini).
English: 0.72 mL of solution in 1.5 mL cartridge (type I glass) with a grey rubber piston and an aluminium crimp-cap with a rubber inlay.
Estonian: Puregon'i süstelahuse 600 RÜ/0,72 ml karp sisaldab 1 kolbampulli (1,5 ml) follitropiin beetat ja 6 süstenõela kasutamiseks koos Puregon Pen pensüsteliga.
English: 0.36 mL of solution in 1.5 mL cartridge (type I glass) with a grey rubber piston and an aluminium crimp-cap with a rubber inlay.
Estonian: Puregon'i süstelahuse 300 RÜ/0,36 ml karp sisaldab 1 kolbampulli (1,5 ml) follitropiin beetat ja 6 süstenõela kasutamiseks koos Puregon Pen pensüsteliga.
English: One vial contains 10 microgram of protein (specific in vivo bioactivity equal to approximately 10,000 IU FSH / mg protein).
Estonian: Üks viaal sisaldab 10 mikrogrammi proteiini (spetsiifiline biosaadavus in vivo on võrdne umbes vahekorras 10 000 RÜ FSH / mg proteiini).
English: 0.18 mL of solution in 1.5 mL cartridge (type I glass) with a grey rubber piston and an aluminium crimp-cap with a rubber inlay.
Estonian: Puregon'i süstelahuse 150 RÜ/0,18 ml karp sisaldab 1 kolbampulli (1,5 ml) follitropiin beetat ja 3 süstenõela kasutamiseks koos Puregon Pen pensüsteliga.
English: Puregon 150 IU/0.5 mL solution for injection
Estonian: Puregon 150 RÜ/0,5 ml süstelahus
English: Puregon 200 IU/0.5 mL solution for injection
Estonian: Puregon 200 RÜ/0,5 ml süstelahus
English: Puregon 100 IU/0.5 mL solution for injection
Estonian: Puregon 100 RÜ/0,5 ml süstelahus
English: Further information on Rasilez HCT can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Lisateave ravimi Rasilez HCT kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Rasilez HCT received a marketing authorisation valid throughout the EU on 16 January 2009.
Estonian: Rasilez HCT on saanud müügiloa, mis kehtib kogu ELis, 16. jaanuaril 2009.
English: Aliskiren on its own has been authorised in the EU since August 2007 as Rasilez, Sprimeo and Riprazo.
Estonian: Aliskireen eraldi on ELis heaks kiidetud alates 2007. aasta augustist ravimitena Rasilez, Sprimeo ja Riprazo.
English: Overall, the company presented the results of nine main studies involving a total of almost 9,000 patients with essential hypertension.
Estonian: Ettevõte esitas kokku ligi 9000 essentsiaalse hüpertensiooniga patsienti hõlmanud 9 põhiuuringu tulemused.
English: Rasilez HCT can only be obtained with a prescription and it is available as tablets (150 mg/12.5 mg; 150 mg/25 mg; 300 mg /12.5 mg; 300 mg/25 mg).The recommended dose of Rasilez HCT is one tablet per day.
Estonian: Seda turustatakse tablettidena (150 mg / 12,5 mg; 150 mg / 25 mg; 300 mg / 12,5 mg; 300 mg / 25 mg).
English: Rasilez HCT is for use in adults only; it must not be used in children aged less than 2 years and is not recommended for older children.
Estonian: Rasilez HTC on ette nähtud ainult täiskasvanutele; seda ei tohi kasutada alla 2-aastased lapsed ja seda ei soovitata vanematele lastele.
English: The European Medicines Agency decided that Rasilez HCT's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et ravimi Rasilez HCT kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: What measures are being taken to ensure the safe and effective use of Rasilez HCT?
Estonian: Mis meetmed võetakse, et tagada ravimi Rasilez HCT ohutu ja efektiivne kasutamine?
English: What is Rasilez HCT and what is it used for?
Estonian: Mis on Rasilez HCT ja milleks seda kasutatakse?
English: Side effects reported with Rasilez HCT are carefully evaluated and any necessary action taken to protect patients.
Estonian: Rasilez HCT kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Rasilez HCT (aliskiren / hydrochlorothiazide)
Estonian: Rasilez HCT (aliskireen/hüdroklorotiasiid)
English: The most common side effect with Rasilez HCT (which may affect between 1 and 10 patients in 100) is diarrhoea.
Estonian: Ravimi Rasilez HCT kõige sagedam kõrvalnäht (võib esineda 1-10 patsiendil 100st) on kõhulahtisus.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rasilez HCT have been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Rasilez HCT ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: As for all medicines, data on the use of Rasilez HCT are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse ravimi Rasilez HCT kasutamise kohta pidevat järelevalvet.
English: Side effects are similar to those of the two active substances.
Estonian: Ravimi kõrvalnähud sarnanevad kahe toimeaine kõrvalnähtudega.
English: For more information about using Rasilez HCT, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet ravimi Rasilez HCT kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Rasilez HCT is a medicine used to treat essential hypertension (high blood pressure) in adults.
Estonian: Rasilez HCT on ravim, mida kasutatakse essentsiaalse hüpertensiooni (kõrgvererõhutõve) raviks täiskasvanutel.
English: Three additional studies showed that the active substances were absorbed in the body in the same way when taken as separate tablets and as Rasilez HCT.
Estonian: Kolmes lisauuringus tõendati, et toimeained imendusid organismis nii eraldi tablettidena kui ka ravimist Rasilez HCT ühesugusel viisil.
English: Rasilez HCT should not be taken together with fruit juice or drinks containing plant extracts such as herbal teas.
Estonian: Rasilez HCT manustamise ajal ei tohi juua puuviljamahla ega taimeekstrakte sisaldavaid jooke, näiteks taimeteed.
English: Other common side effects (which may affect more than 1 in 10 patients) that have been observed with hydrochlorothiazide alone are hypokalaemia (low blood potassium levels) and increases in blood cholesterol and triglyceride (a type of fat) levels.
Estonian: Muud sagedad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) ainult hüdroklorotiasiidi kasutamisel on hüpokaleemia (vere kaaliumivaegus) ning vere kolesterooli- ja triglütseriidisisalduse (teatud rasvade sisalduse) suurenemine.
English: The company presented information used in the assessment of aliskiren and from the published literature to support its application for Rasilez HCT, as well as information from additional studies.
Estonian: Ettevõte esitas ravimi Rasilez HCT müügiloa taotluse toetuseks teabe, mida kasutati aliskireeni hindamiseks, samuti kirjanduses avaldatud ning lisauuringutest saadud teabe.
English: The studies lasted for between 8 weeks and a year, and the main measure of effectiveness was the change in blood pressure either during the resting phase of the heartbeat (diastolic) or when the chambers of the heart were contracting (systolic).
Estonian: Uuringute kestus oli 8 nädalast aastani ning nende efektiivsuse põhinäitaja oli kas diastoolse või süstoolse vererõhu (vastavalt nn alumine ja ülemine vererõhk) muutus.
English: The studies compared the combination of aliskiren and hydrochlorothiazide with placebo (a dummy treatment), with aliskiren or hydrochlorothiazide taken alone, or with other medicines for hypertension (valsartan, irbesartan, lisinopril or amlodipine).
Estonian: Uuringutes võrreldi aliskireeni ja hüdroklorotiasiidi kombinatsiooni platseeboga (näiv ravim), eraldi võetud aliskireeniga või hüdroklorotiasiidiga või muude kõrgvererõhuravimitega (valsartaan, irbesartaan, lisinopriil, amlodipiin).
English: Patients previously taking only aliskiren or hydrochlorothiazide may need to take the two substances as separate tablets and adjust the doses before switching to Rasilez HCT.
Estonian: Patsientidel, kes said varem üksnes aliskireeni või hüdroklorotiasiidi, võib olla vaja võtta kumbagi toimeainet eraldi tablettidena ja kohandada enne ravimile Rasilez HCT üleminekut annuseid.